Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and ...

Clinical neuroscientist Joe Schacht offered an overview of the research on weight-loss drugs for alcoholism, other potential ...

Weight-loss drugs are increasingly popular among employees but weigh heavily on health-insurance budgets. Popular weight-loss drugs such as Ozempic, Wegovy and Zepbound are a growing factor in ...

The company created its GLP-1 Insurance Checker specifically to help you determine your coverage on popular weight loss drugs like Ozempic, Wegovy, and Zepbound. If you're new to Ro, they'll even ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Covering some 1.9million people in the UK, private health insurer Vitality has become the country’s first provider to offer customers discounted weight-loss treatments, such as Wegovy and Mounjaro.

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.